Skip to main content
. 2016 Apr 26;7(26):39556–39571. doi: 10.18632/oncotarget.9005

Figure 1. Expression of full length cytoplasmic TBLR1 (cTBLR1) and protease cleaved cytoplasmic variant of TBLR1 (cvTBLR1) in prostate cancer cells.

Figure 1

Figure 1

(A) Relative total expression of TBLR1 and cvTBLR1 in androgen-dependent LNCaP cells compared to androgen-independent LNCaP-AI and PC-3 cells. (B) Confirmation of faster migrating band (cvTBLR1) as a TBLR1 variant by knockdown with TBLR1 specific siRNA in LNCaP-AI cells. (C) Relative expression and localization of TBLR1 and cvTBLR1 in prostate cancer cells by western blot of fractionated lysates. (D) Quantification of fractionation western blot comparing localization and relative expression of TBLR1 and cvTBLR1 in prostate cancer cells. (E) Overexpression of cytoplasmic TBLR1 using nuclear export sequence (NES) fused TBLR1 construct to create LNCaP –NESTBLR1 cells. (F) LNCaP pBabe cells after 6 days in hormone free media. (G) LNCaP NESTBLR1 cells after 6 days in hormone free media. (H) Caspase 3/7 luciferase assay measuring apoptosis in LNCaP pBabe and LNCaP NESTBLR1 cells in hormone free media. (I) Caspase 3/7 luciferase assay measuring apoptosis in LNCaP pBabe and LNCaP NESTBLR1 cells in 150 μM bicalutamide media. (J) Quantification of the percentage of TUNEL-positive cells of LNCaP pBabe vs. LNCaP NESTBLR1 cells in hormone free media or 150 μM bicalutamide media. (K) TUNEL staining on LNCaP control vs. LNCaP NESTBLR1 cells in androgen free and androgen media with (L) 150 μM bicalutamide treatment.